DURECT Provides Update on CHRONOGESIC(R) Research Program

Download PDF:

CUPERTINO, Calif., April 7, 2008 /PRNewswire-FirstCall/ — DURECT
Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals has
stated that it intends to return the rights to CHRONOGESIC(R) licensed from
DURECT Corporation for the U.S. and Canada. CHRONOGESIC is a product
candidate consisting of a sufentanil containing implantable device intended
for the treatment of moderate-to-severe chronic pain. As a result, the
Development, Commercialization and Supply License Agreement between Endo and
DURECT entered into in November 2002 will terminate. This return of
CHRONOGESIC rights has no effect on DURECT and Endo’s collaboration with
respect to the sufentanil transdermal patch (TRANSDUR(TM)-Sufentanil) licensed
by Endo from DURECT for the U.S. and Canada.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies focused on treating chronic and episodic
diseases and conditions. The Company currently has multiple late-stage
pharmaceutical products in development initially focused on significant unmet
medical needs in pain management, with a number of research programs underway
in a variety of other therapeutic areas. For more information, please visit

Corporation. Other referenced trademarks belong to their respective owners.
TRANSDUR-Sufentanil is a drug candidate under development and has not been
submitted or approved for commercialization by the US Food and Drug
Administration or other health authorities.

DURECT Forward-Looking Statement

The statement in this press release regarding DURECT’s emergence as a
specialty pharmaceutical company and DURECT’s product candidates are forward-
looking statements involving risks and uncertainties that can cause actual
results to differ materially from those in such forward-looking statements.
Potential risks and uncertainties include, but are not limited to, DURECT’s
(and that of its third party collaborators where applicable) abilities to
obtain approvals from regulatory agencies with respect to its development
activities and product candidates, design, enroll, conduct and complete
clinical trials, complete the design, development, and manufacturing process
development of the product candidates, consummate collaborative agreements
relating to our product candidates and technologies, manufacture and
commercialize the product candidates, obtain marketplace acceptance of the
product candidates and manage and obtain capital to fund its growth,
operations and expenses. Further information regarding these and other risks
is included in DURECT’s Form 10-K dated March 13, 2008 under the heading “Risk

CONTACT: Matt Hogan, Chief Financial Officer of DURECT Corporation,
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Web site: http://www.www.durect.com

Scroll to Top